Statistiche di base
| CIK | 1888014 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Akanda Corp.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 100 King Street W, Suite 1600 Toronto, Ontario M5X 1G5, Canada (Address of principal executive office) Indicate b |
|
| August 22, 2025 |
Exhibit 99.2 Docusign Envelope ID: 2B493802 - 195D - 43E2 - B94A - 173A1C4C7D61 Docusign Envelope ID: 2B493802 - 195D - 43E2 - B94A - 173A1C4C7D61 Docusign Envelope ID: 2B493802 - 195D - 43E2 - B94A - 173A1C4C7D61 |
|
| August 22, 2025 |
Exhibit 10.3 DEBT SETTLEMENT AGREEMENT THIS DEBT SETTLEMENT AGREEMENT is made effective the 19th day of August 2025. BETWEEN: FIRST TOWERS & FIBERS CORP., a company incorporated pursuant to the laws of the Province of British Columbia (the “Company”) AND: pgc finco inC. (as successor to PLENARY GROUP (CANADA) FINCO INC.), a company incorporated pursuant to the laws of the Province of British Colum |
|
| August 22, 2025 |
Exhibit 99.1 AKANDA CORP. ANNOUNCES CLOSING OF SHARE EXCHANGE WITH FIRST TOWERS AND FIBER CORP. First Towers develops, constructs and owns telecommunications infrastructure in Mexico Akanda Reaffirms its Continued Focus on the Growth of its Pre-Revenue Canadian Farming Property in British Columbia, at which the Company Plans to Develop THC and CBD Facilities Toronto, Ontario, August 22, 2025 (News |
|
| August 22, 2025 |
Exhibit 10.7 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITI |
|
| August 22, 2025 |
Exhibit 10.6 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR THE LAWS OF ANY OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDE |
|
| August 22, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 19, 2025, is by and among Akanda Corp., a corporation existing under the laws of the Province of Ontario (the “Company”), and First Towers & Fiber Corp., a corporation existing under the laws of the Province of British Columbia (“First Towers”), on behalf of certain of the common sh |
|
| August 22, 2025 |
Akanda Corp. Announces Reverse Stock Split Exhibit 99.1 Akanda Corp. Announces Reverse Stock Split TORONTO, ON August 22, 2025 — Akanda Corp. (NASDAQ: AKAN) (the “Company” or “Akanda”), today announced that it expects to implement a 1-for-3.125 reverse stock split of the Company’s common shares effective August 26, 2025. The reverse stock split was previously approved by the Company’s shareholders on April 30, 2025 and Board of Directors o |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 100 King Street W, Suite 1600 Toronto, Ontario M5X 1G5, Canada (Address of principal executive office) Indicate b |
|
| August 22, 2025 |
Exhibit 10.5 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR THE LAWS OF ANY OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDE |
|
| August 22, 2025 |
Exhibit 10.8 GENERAL SECURITY AGREEMENT This General Security Agreement is made as of August 19, 2025 TO: 1353744 B.C. Ltd. (the “Lender”) RECITALS: A. Akanda Corp. (the “Borrower”) is, or may become, indebted or liable to the Lender pursuant to the terms of the Promissory Note. B. To secure the payment and performance of the Secured Liabilities, the Borrower has agreed to grant to the Lender the |
|
| August 22, 2025 |
SECOND AMENDMENT TO SHARE EXCHANGE AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO SHARE EXCHANGE AGREEMENT This Second Amendment (this “Amendment”) to the Share Exchange Agreement dated as of March 5, 2025 and amended as of March 31, 2025 (the “Agreement”), among Akanda Corp., a corporation existing under the laws of the Province of Ontario, First Towers & Fiber Corp., a corporation existing under the laws of the Province of British Columbia, an |
|
| August 22, 2025 |
Exhibit 10.4 DEBT SETTLEMENT AGREEMENT THIS DEBT SETTLEMENT AGREEMENT is made effective the 19th day of August 2025. BETWEEN: FIRST TOWERS & FIBERS CORP., a company incorporated pursuant to the laws of the Province of British Columbia (the “Company”) AND: DUNSTAN HOLDINGS LTD., a company incorporated pursuant to the laws of the Province of British Columbia (the “Creditor”) AND: AKANDA CORP., a com |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) c/o Gowling WLG 100 King St. W, Suite 1600 Toronto, ON M5X 1G5 (Address of principal executive office) Indicate b |
|
| August 8, 2025 |
Exhibit 99.2 DN: AKANDA CORP. Form of Proxy – Special Meeting to be held on August 29, 2025 Trader’s Bank Building 1100 , 67 Yonge Street Toronto ON M 5 E 1 J 8 Print the name of the person you are appointing if this person is someone other than the Management Nominees listed herein: Appointment of Proxyholder I/We being the undersigned holder(s) of Akanda Corp. hereby appoint Jatinder Dhaliwal or |
|
| August 8, 2025 |
Exhibit 99.1 AKANDA CORP. NOTICE OF SPECIAL MEETING TO BE HELD ON AUGUST 29, 2025 AND MANAGEMENT INFORMATION CIRCULAR JULY 29, 2025 - i - AKANDA CORP. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS (the “Notice”) NOTICE IS HEREBY GIVEN that a special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (the “Common Shares”) of Akanda Corp. (the “Corporation”) will be held in per |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 100 King Street W, Suite 1600 Toronto, Ontario M5X 1G5, Canada (Address of principal executive office) Indicate by c |
|
| April 30, 2025 |
PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the Annual Report on Form 20-F of Akanda Corp. (the “Company”) for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act o |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2025 |
PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the Annual Report on Form 20-F of Akanda Corp. (the “Company”) for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act o |
|
| April 30, 2025 |
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934) Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934) I, Katie Field, certify that: 1. I have reviewed this Annual Report on Form 20-F of Akanda Corp.. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circums |
|
| April 30, 2025 |
To the Board of Directors of Akanda Corp. Exhibit 15.1 To the Board of Directors of Akanda Corp. We hereby consent to the incorporation by reference in each of the Akanda Corp.’s Registration Statements on Form S-8 (No. 264450, No. 267976, No. 273245 and No. 279381) of our report dated April 30, 2024, relating to the consolidated financial statements of Akanda Corp., which appears in this Form 20-F. April 30, 2025 We have served as the Co |
|
| April 30, 2025 |
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934) Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934) I, Gurcharn Deol, certify that: 1. I have reviewed this Annual Report on Form 20-F of Akanda Corp.. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 100 King Street W, Suite 1600 Toronto, Ontario M5X 1G5, Canada (Address of principal executive office) Indicate by |
|
| April 16, 2025 |
Exhibit 99.1 AKANDA CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING TO BE HELD ON APRIL 30, 2025 AND MANAGEMENT INFORMATION CIRCULAR APRIL 11, 2025 - i - AKANDA CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS (the “Notice”) NOTICE IS HEREBY GIVEN that an annual general and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (the “Common Shares |
|
| April 16, 2025 |
Exhibit 99.2 |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 100 King Street W, Suite 1600 Toronto, Ontario M5X 1G5, Canada (Address of principal executive office) Indicate by |
|
| April 1, 2025 |
Exhibit 10.1 Akanda Corp. An Ontario corporation Offering of 226,668 Common Shares (Pursuant to Rule 506(b) of Regulation D) AN INVESTMENT IN THE SECURITIES INCLUDED IN THE OFFERING DESCRIBED HEREIN, INVOLVES RISK. INVESTORS SHOULD NOT INVEST ANY FUNDS IN THE OFFERING UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATIO |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) c/o Gowling WLG 100 King St. W, Suite 1600 Toronto, ON M5X 1G5 (Address of principal executive office) Indicate by |
|
| April 1, 2025 |
FIRST AMENDMENT TO SHARE EXCHANGE AGREEMENT Exhibit 10.2 FIRST AMENDMENT TO SHARE EXCHANGE AGREEMENT This First Amendment (this “Amendment”) to the Share Exchange Agreement (the “Agreement”) dated as of March 5, 2025 between Akanda Corp., a corporation existing under the laws of the Province of Ontario, and First Towers & Fiber Corp., a corporation existing under the laws of the Province of British Columbia, is made as of the 31st day of Ma |
|
| March 11, 2025 |
Exhibit 99.2 AKANDA CORP. ANNOUNCES SHARE EXCHANGE AGREEMENT WITH FIRST TOWERS AND FIBER CORP. First Towers develops, constructs and owns telecommunications infrastructure in Mexico Akanda Reaffirms its Continued Focus on the Growth of its Pre-Revenue Canadian Farming Property in British Columbia, at which the Company Plans to Develop THC and CBD Facilities Intends to Discontinue and Cease its Bus |
|
| March 11, 2025 |
Exhibit 99.1 SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT is made effective as of March 5, 2025 (the “Execution Date”) AMONG: AKANDA CORP., a corporation existing under the laws of the Province of Ontario (hereinafter referred to as “Purchaser”) AND: FIRST TOWERS & FIBERS CORP., a corporation existing under the laws of the Province of British Columbia (hereinafter referred to as “Company |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| November 26, 2024 |
Bridge LOAN Agreement FIRST TOWERS & FIBER CORP. – and – AKANDA CORP. November 21, 2024 Exhibit 10.1 Bridge LOAN Agreement BETWEEN FIRST TOWERS & FIBER CORP. – and – AKANDA CORP. November 21, 2024 Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Certain Rules of Interpretation 5 1.3 Governing Law 5 1.4 Entire Agreement 5 1.5 Time of Day 6 1.6 Business Day 6 1.7 Conflicts 6 Article 2 loan 6 2.1 Loan 6 2.2 Purpose 6 2.3 Loan—Notice and Limitations 6 2.4 Funding of Loan 7 2.5 Lender’s R |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| November 12, 2024 |
Exhibit 99.2 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| November 12, 2024 |
Akanda Corp. Announces Reverse Stock Split Exhibit 99.1 Akanda Corp. Announces Reverse Stock Split LONDON, UK November 12, 2024 — Akanda Corp. (NASDAQ: AKAN) (the “Company” or “Akanda”), today announced that it expects to implement a 1-for-2 reverse stock split of the Company’s common shares effective November 14, 2024. The reverse stock split was previously approved by the Company’s shareholders on March 22, 2024 and Board of Directors on |
|
| October 30, 2024 |
Exhibit 99.1 Akanda Corp. Unaudited Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) As at June 30, December 31, Note 2024 2023 ASSETS Current Cash $ 6,013,262 $ 82,816 Cash held in trust 18,720 11,059 Trade and other receivables 6 311,721 284,513 Prepayments 1,270,515 140,583 Inventory 7 – 1,286,894 Total Current Assets 7,614,218 1,805,865 Non-C |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by chec |
|
| October 4, 2024 |
Akanda Corp. Announces Closing of Underwritten Public Offering Exhibit 99.1 Akanda Corp. Announces Closing of Underwritten Public Offering London, October 4, 2024 – On October 2, 2024, Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, entered into an underwriting agreement (the “Underwriting Agreement”) with Univest Securities, LLC (“Univest”) as the underwriter in connection with the issuance and sale by the |
|
| October 4, 2024 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: Initial Exercise Date: [] THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| October 4, 2024 |
AKANDA CORP. UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION VERSION AKANDA CORP. UNDERWRITING AGREEMENT October 2, 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, AKANDA CORP., a corporation organized under the laws of the Province of Ontario (collectively with its subsidiaries and affiliates, includ |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by chec |
|
| October 3, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-281945 PROSPECTUS 258,940 Common Shares 1,241,060 Pre-Funded Warrants to Purchase 1,241,060 Common Shares 1,241,060 Common Shares Underlying the Pre-Funded Warrants Akanda Corp. We are offering 258,940 Common Shares, no par value (the “Common Shares”) at a public offering price of $1.00 per share. We are also offering 1,241,060 pre-funded warra |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41324 AKANDA CORP. (Exact Name of Registrant as Specified in Charter) Akanda Corp. 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom Tel: +44 (203 |
|
| October 2, 2024 |
Akanda Corp. Announces Pricing of Underwritten Public Offering Exhibit 99.1 Akanda Corp. Announces Pricing of Underwritten Public Offering London, October 2, 2024 – Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, today announced that it has entered into a firm commitment underwriting agreement with Univest Securities, LLC, as underwriter, whereby Univest has agreed to purchase 1,500,000 common shares (or pre |
|
| September 27, 2024 |
AKANDA CORP. 1a, 1b Learoyd Road New Romney, TN28 8XU, United Kingdom Tel: +44 (203) 488-9514 CORRESP 1 filename1.htm AKANDA CORP. 1a, 1b Learoyd Road New Romney, TN28 8XU, United Kingdom Tel: +44 (203) 488-9514 September 27, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form F-1 (File No. 333-281945) Ladies and Gentlemen: Purs |
|
| September 27, 2024 |
September 27, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Akanda Corp. Registration Statement on Form F-1, as amended File No. 333-281945 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the |
|
| September 20, 2024 |
As filed with the Securities and Exchange Commission on September 20, 2024 As filed with the Securities and Exchange Commission on September 20, 2024 Registration No. |
|
| September 20, 2024 |
AKANDA CORP. UNDERWRITING AGREEMENT Exhibit 1.1 AKANDA CORP. UNDERWRITING AGREEMENT September [●], 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, AKANDA CORP., a corporation organized under the laws of the Province of Ontario (collectively with its subsidiaries and affiliates, including, without l |
|
| September 20, 2024 |
Exhibit 21.1 Subsidiaries Subsidiaries Jurisdiction of Incorporation Canmart Limited England and Wales Cannahealth Limited Malta Bophelo Holdings Ltd. United Kingdom Holigen Limited Malta 1468243 B.C. Ltd. Canada 1371011 B.C. Ltd Canada |
|
| September 16, 2024 |
Akanda Corp. Secures Hemp Cultivation License in Canada, Building on Previous Development Agreement Exhibit 99.1 Akanda Corp. Secures Hemp Cultivation License in Canada, Building on Previous Development Agreement London, United Kingdom – September 16, 2024 – Akanda Corp. (NASDAQ: AKAN), a global cannabis company, is excited to announce that it has obtained a license for hemp cultivation in Canada. This license is directly tied to Akanda’s previously announced agreement with 1107385 B.C. LTD, fur |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-41324 AKANDA CORP. (Exact Name of Registrant as Specified in Charter) Akanda Corp. 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom Tel: +44 (2 |
|
| September 5, 2024 |
As filed with the Securities and Exchange Commission on September 5, 2024 As filed with the Securities and Exchange Commission on September 5, 2024 Registration No. |
|
| September 5, 2024 |
Exhibit 21.1 Subsidiaries Subsidiaries Jurisdiction of Incorporation Canmart Limited England and Wales Cannahealth Limited Malta Bophelo Holdings Ltd. United Kingdom Holigen Holdings Limited Malta 1468243 B.C. Ltd. Canada 1371011 B.C. Ltd Canada |
|
| September 5, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Akanda Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check m |
|
| June 14, 2024 |
Akanda Corporation announces completion of F-3 shelf registration statement Exhibit 99.1 Akanda Corporation announces completion of F-3 shelf registration statement London, United Kingdom-(Newsfile Corp. - June 14, 2024) - Akanda Corp. (NASDAQ: AKAN) (“Akanda” or the “Company”), an international medical cannabis company, today announced that it has successfully completed sales of its securities under its existing Form F-3 shelf registration. The shelf registration stateme |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check m |
|
| June 12, 2024 |
Akanda Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement Exhibit 99.1 Akanda Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement London, UK, June 12, 2024 - Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, today announced that it has received a letter (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) dated June 7, 2024, inform |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check m |
|
| May 23, 2024 |
Exhibit 99.2 |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check ma |
|
| May 23, 2024 |
AKANDA ANNOUNCES STOCK CONSOLIDATION Exhibit 99.1 AKANDA ANNOUNCES STOCK CONSOLIDATION London, UK May 21, 2024 –Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, reported that it expects to implement a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary share |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check ma |
|
| May 20, 2024 |
Akanda Announces Closing of Subsequent Registered Direct Offering Exhibit 99.3 Akanda Announces Closing of Subsequent Registered Direct Offering London, UK May 20, 2024 – Akanda Corp. ("Akanda" or the “Company”), (NASDAQ: AKAN) an international medical cannabis company, today announced that it has closed its previously announced second registered direct offering for the sale and issuance of 2,491,381common shares at a purchase price of $0.1031 and 12,057,600 pre |
|
| May 20, 2024 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 29, 2024) Registration No. |
|
| May 20, 2024 |
Akanda Corp. Announces Subsequent Registered Direct Offering Exhibit 99.2 Akanda Corp. Announces Subsequent Registered Direct Offering London, May 17, 2024 – Akanda Corp. (“Akanda” or the “Company”), an international medical cannabis company, today announced that it has entered into a second securities purchase agreement with an accredited investor whereby the investor has agreed to purchase 2,491,381common shares at a purchase price of $0.1031 and 12,057,6 |
|
| May 20, 2024 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: Initial Exercise Date: May , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 20, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May , 2024, between Akanda Corp., a Canadian corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). W |
|
| May 20, 2024 |
Akanda Announces Closing of Registered Direct Offering Exhibit 99.1 Akanda Announces Closing of Registered Direct Offering London, May 17, 2024 – Akanda Corp. (“Akanda” or the “Company”), an international medical cannabis company, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 2,491,381common shares at a purchase price of $0.1031 per share, and 21,756,922 pre-funded warrants to purch |
|
| May 17, 2024 |
Akanda Corp. Announces Registered Direct Offering Exhibit 99.1 Akanda Corp. Announces Registered Direct Offering London, May 17, 2024 – Akanda Corp. ("Akanda" or the “Company”), an international medical cannabis company, today announced that it has entered into a securities purchase agreement with an accredited investor whereby the investor has agreed to purchase 2,491,381 common shares at a purchase price of $0.1031 and 21,756,922 pre-funded war |
|
| May 17, 2024 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 29, 2024) Registration No. |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check ma |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check ma |
|
| May 16, 2024 |
AKANDA CORP. RECEIVES NOTICE OF NON-COMPLIANCE FROM NASDAQ Exhibit 99.1 AKANDA CORP. RECEIVES NOTICE OF NON-COMPLIANCE FROM NASDAQ London, UK May 16, 2024 –Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), announced that it has received a deficiency notification letter from the Nasdaq Listing Qualifications Department on May 14, 2024, due to non-compliance with the minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550(b) |
|
| May 14, 2024 |
AKANDA CORP ANNOUNCES SETTLEMENT AGREEMENT WITH FORMER CEO TEJINDER VIRK Exhibit 99.1 AKANDA CORP ANNOUNCES SETTLEMENT AGREEMENT WITH FORMER CEO TEJINDER VIRK London, UK May 13, 2024 –Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), today announced a settlement agreement with former chief executive officer and director, Tejinder Virk, concluding a series of disputes that commenced following Mr. Virk’s resignation on February 3, 2023. The settlement resolves all |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check ma |
|
| May 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akanda Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Proposed Maximum Maximum Security Fee Calculation Amount Offering Price Per Aggregate Offering Amount of Registration Security Type Class Title Rule Registered(1) Unit(3) Price(3) Fee Rate Fee Equity Common Shares(2) 457(c) and 4 |
|
| May 13, 2024 |
As filed with the Securities and Exchange Commission on May 13, 2024 As filed with the Securities and Exchange Commission on May 13, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 99.1 Akanda Corp. Announces Plans to Be Among International First Movers Pending Completion of Landmark Change in US Drug Policy London, United Kingdom-(Newsfile Corp. – May 10, 2024) - Akanda Corp. (NASDAQ: AKAN) (“Akanda” or the “Company”), an international medical cannabis company, today announces it is actively following the landmark change in federal US policy to reschedule cannabis u |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check ma |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 1, 2024 |
DATED 15 JANUARY 2024 Settlement agreement CANMART LTD AKANDA CORP MR. TREVOR SCOTT Exhibit 4.33 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed. DATED 15 JANUARY 2024 Settlement agreement between CANMART LTD and AKANDA CORP and MR. TREVOR SCOTT This agreement is dated 2024 Parties (1) CANMART LTD incorporated and regist |
|
| May 1, 2024 |
RESIGNATION AND MUTUAL RELEASE Exhibit 4.32 RESIGNATION AND MUTUAL RELEASE THIS AGREEMENT, dated April 24, 2024 (the “Effective Date”), is made by and between Harvinder Singh (the “Individual”) and Akanda Corp. (the “Company”). In consideration of the terms and conditions contained in this Agreement, the parties hereby agree as follows: 1. Resignation. The Individual hereby resigns as a director and officer of the Company, effe |
|
| May 1, 2024 |
Exhibit 12.1 Certification of the Chief Executive Officer as required by Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Katie Field, certify that: 1. I have reviewed this annual report on Form 20-F of Akanda Corp; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| May 1, 2024 |
AKANDA CORP. INCENTIVE COMPENSATION RECOVERY POLICY Exhibit 97.1 AKANDA CORP. INCENTIVE COMPENSATION RECOVERY POLICY The Board of Directors (the “Board”) of Akanda Corp. (the “Company”) has adopted this Incentive Compensation Recovery Policy (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy that are not defined elsewhere in the text of this Policy are defined in Section 12. 1. Persons Sub |
|
| May 1, 2024 |
INSIDER TRADING POLICY (Adopted as of November 14, 2021) Exhibit 11.4 INSIDER TRADING POLICY (Adopted as of November 14, 2021) I. SUMMARY Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Akanda Corp. (together with its subsidiaries, the “Company”) as well as that of all persons affiliated with the Company. “Insider trading” occurs when any person purchases or sells a security while in |
|
| May 1, 2024 |
To the Board of Directors of Akanda Corp. Exhibit 15.1 To the Board of Directors of Akanda Corp. We hereby consent to the incorporation by reference in each of the Akanda Corp.’s Registration Statements on Form S-8 (No. 264450, No. 267976 and No. 273245) of our report dated April 30, 2024, relating to the consolidated financial statements of Akanda Corp., which appears in this Form 20-F. May 1, 2024 We have served as the Company’s auditor |
|
| May 1, 2024 |
AKANDA CORP. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: february 26, 2024 Exhibit 4.31 AKANDA CORP. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: february 26, 2024 1. GENERAL. (a) Eligible Award Recipients. Employees, Officers, Directors and Consultants are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Stock Options, and (ii) Restricted Share Unit Awards. (c) Purpose. The Plan, thr |
|
| May 1, 2024 |
Exhibit 13.1 Certification of the Chief Executive Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Katie Field, Interim Chief Executive Officer and Directo |
|
| May 1, 2024 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of April 30, 2024, Akanda Corp. (the “Company”, “we”, “us” and “our”) had the following series of securities that were outstanding and registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act: Title of each class Trad |
|
| May 1, 2024 |
Exhibit 12.2 Certification of the Chief Financial Officer as required by Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Gurcharn Deol, certify that: 1. I have reviewed this annual report on Form 20-F of Akanda Corp; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements mad |
|
| May 1, 2024 |
Exhibit 13.2 Certification of the Chief Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Gurcharn Deol, Chief Financial Officer of Akanda Corp. ( |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.50 SEC FILE NUMBER CUSIP NUMBER (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Rep |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| April 26, 2024 |
AKANDA APPOINTS COOPER TO THE BOARD OF DIRECTORS Exhibit 99.1 AKANDA APPOINTS COOPER TO THE BOARD OF DIRECTORS London, UK April 25, 2024 –Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, Akanda Corp. announces the appointment of Christopher Cooper to its board of directors following the resignation of Harvinder Singh as a director. Mr. Christopher Cooper has over 20 years of extensive business e |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| April 15, 2024 |
Akanda Announces No Equity Financing Until Further Notice Exhibit 99.1 Akanda Announces No Equity Financing Until Further Notice London, UK April 15, 2024 –Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, previously announced the completion of several public offerings and the sale of its indirectly wholly-owned Portuguese subsidiary, RPK BioPharma Unipessoal, LDA (“RPK”) now announces its plans to pause |
|
| April 12, 2024 |
Akanda Announces Plans to Enter Blockchain and AI Technology Sector Exhibit 99.2 Akanda Announces Plans to Enter Blockchain and AI Technology Sector London,UK April 12, 2024 –Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, Akanda Corp. announces its plans to enter the blockchain and artificial intelligence sector of the cannabis industry. With an increasingly complex and global supply chain for the international |
|
| April 12, 2024 |
Exhibit 99.1 Akanda Looks to Commercialize and Capitalize on Germany’s Legalization of Cannabis, Opening Path to $3BN Market London, UK April 12, 2024 –Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, announces its plans to evaluate and pursue strategic investments in the expanded legalized German market. On April 1, 2024 Germany became the third |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| April 11, 2024 |
Akanda Corp. Announces Plan to Integrate Technology Solutions to Capture UK Market Exhibit 99.2 Akanda Corp. Announces Plan to Integrate Technology Solutions to Capture UK Market London, Thursday April 11, 2024 – on April 4, 2024, Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company announced its wholly-owned United Kingdom (UK) subsidiary, Canmart, plans to develop its social shopping capability by integrating with META, to create a |
|
| April 11, 2024 |
Akanda Corp. Announces Closing of the Sale of RPK Exhibit 99.1 Akanda Corp. Announces Closing of the Sale of RPK London, April 11, 2024 – on April 1 2024, Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, Akanda Corp. completed the transaction with Somai Pharmaceuticals Ltd. (the “Buyer”) for the sale of RPK, its indirect wholly-owned Portuguese subsidiary. Pursuant to the provisions set forth in |
|
| March 28, 2024 |
Exhibit 10.1 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to Akanda Corp (“you,” the “Client” or the “Company”) as more fully described in this agreement (the Agreement”). This Agreement sets forth the terms and conditions pursuant to which the Company engages the Consultant to provide such services. 1. Consulting Services. |
|
| March 28, 2024 |
Exhibit 99.2 Akanda Corp. Announces Canmart’s Plans for Facebook and Instagram Social Shopping Technology Integration London, March 28, 2024 – on March 28, 2024, Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, Akanda Corp. announced its wholly-owned United Kingdom (UK) subsidiary, Canmart, plans to develop its social shopping capability by integr |
|
| March 28, 2024 |
Exhibit 99.1 Akanda Corp. Announces Strategic Plan to Evaluate and Enter Bitcoin, Blockchain, AI Segments of the Cannabis Market London, March 28, 2024 – on March 28, 2024, Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, Akanda Corp. announced aspirations to enter technology segments of the cannabis industry. The Company is evaluating potential o |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 27, 2024 |
AKANDA CORP. UNDERWRITING AGREEMENT Exhibit 1.1 AKANDA CORP. UNDERWRITING AGREEMENT March 24, 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, AKANDA CORP., a corporation organized under the laws of the Province of Ontario (collectively with its subsidiaries and affiliates, including, without limita |
|
| March 27, 2024 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: Initial Exercise Date: [], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 27, 2024 |
Akanda Corp. Announces Closing of Underwritten Public Offering Exhibit 99.1 Akanda Corp. Announces Closing of Underwritten Public Offering London, March 27, 2024 – On March 24, 2024, Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, entered into an underwriting agreement (the “Underwriting Agreement”) with Univest Securities, LLC (“Univest”) as the underwriter in connection with the issuance and sale by the Co |
|
| March 26, 2024 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-277182 3,087,443 Common Shares 37,997,190 Pre-Funded Warrants to Purchase 37,997,190 Common Shares 37,997,190 Common Shares Underlying the Pre-Funded Warrants Akanda Corp. We are offering 3,087,443 Common Shares, no par value (the “Common Shares”) at a public offering price of $0.1217. We are also offering 37,997,190 pre-funded warr |
|
| March 25, 2024 |
Akanda Corp. Announces Pricing of Underwritten Public Offering Exhibit 99.1 Akanda Corp. Announces Pricing of Underwritten Public Offering London, March 25, 2024 – Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, today announced that it has entered into a firm commitment underwriting agreement with Univest Securities, LLC, as underwriter, whereby Univest has agreed to purchase up to 41,084,634 common shares o |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 18, 2024 |
Akanda corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom Akanda corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom March 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tamika Sheppard Re: Akanda Corp. (the “Company”) Registration Statement on Form F-1 File No. 333-277182 (the “Registration Statement”) Dear Ms. Sheppard: Pursuant to |
|
| March 18, 2024 |
Univest Securities LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 Univest Securities LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 March 18, 2024 VIA EDGAR U. |
|
| March 18, 2024 |
Univest Securities LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 Univest Securities LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 March 18, 2024 VIA EDGAR U. |
|
| March 18, 2024 |
Akanda corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom Akanda corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom March 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tamika Sheppard Re: Akanda Corp. (the “Company”) Registration Statement on Form F-1 File No. 333-277182 (the “Registration Statement”) Dear Ms. Sheppard: Pursuant to |
|
| March 18, 2024 |
Univest Securities LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 Univest Securities LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 March 18, 2024 VIA EDGAR U. |
|
| March 18, 2024 |
Akanda corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom Akanda corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom March 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tamika Sheppard Re: Akanda Corp. (the “Company”) Registration Statement on Form F-1 File No. 333-277182 (the “Registration Statement”) Dear Ms. Sheppard: Reference i |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 11, 2024 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 10.19 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: Initial Exercise Date: [], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| March 11, 2024 |
Exhibit 10.25 FINDER’S AGREEMENT THIS FINDER’S FEE AGREEMENT is made as of the 12th day of June, 2021 (the “Effective Date”) between Cannera Holdings Ltd, a British Columbia Corporation having an office at [***] (the “Finder”) and AKANDA CORP., a United Kingdom Corporation having an office situated 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (the “Company”). WHEREAS the Finder has agre |
|
| March 11, 2024 |
Exhibit 99.1 AKANDA CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING TO BE HELD ON MARCH 22, 2024 AND MANAGEMENT INFORMATION CIRCULAR MARCH 12, 2024 - i - AKANDA CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS (the “Notice”) NOTICE IS HEREBY GIVEN that an annual general and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (the “Common Shares |
|
| March 11, 2024 |
AKANDA CORP. UNDERWRITING AGREEMENT Exhibit 1.1 AKANDA CORP. UNDERWRITING AGREEMENT , 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, NY 10019 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, AKANDA CORP., a corporation organized under the laws of the Province of Ontario (collectively with its subsidiaries and affiliates, including, without limitation, al |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. |
|
| March 11, 2024 |
Exhibit 99.2 AKANDA CORP. Security Class: Common Shares FORM OF PROXY Annual General & Special Meeting to be held on Friday, March 22, 2024 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any adjournment or |
|
| March 11, 2024 |
Exhibit 107 Calculation Of Filing Fee Table F-1 (Form Type) Akanda Corp. (Exact name of Registrant as Specified in its Charter) Security Type (1) Security Class Title Amount Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee (3) Fees to Be Paid Common Shares, par value $0.0001 per share, to be sold by the Regis |
|
| March 6, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 4, 2024, between Akanda Corp., a Canadian corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”) |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 6, 2024 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: Initial Exercise Date: March , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 5, 2024 |
367,870 common shares Pre-funded warrants to purchase up to 373,002 common shares AKANDA CORP. Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 29, 2024) Registration No. |
|
| March 5, 2024 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: Initial Exercise Date: March , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| March 5, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 1, 2024, between Akanda Corp., a Canadian corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”) |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
|
| March 1, 2024 |
367,870 common shares Pre-funded warrants to purchase up to 361,972 common shares AKANDA CORP. Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 29, 2024) Registration No. |
|
| February 29, 2024 |
Exhibit 99.3 ESCROW AGREEMENT THIS ESCROW AGREEMENT is dated as of February 28, 2024 BETWEEN: AKANDA CORP. (“Akanda”) AND: SOMAI PHARMACEUTICALS LTD. (“Somai”) AND: LAWSON LUNDELL LLP, a limited liability partnership formed under the laws of the Province of British Columbia (the “Escrow Agent”). WHEREAS: A. Pursuant to a Non-Binding Letter of Intent made as of November 21, 2023 between Akanda and |
|
| February 29, 2024 |
Exhibit 99.2 SHARE PURCHASE AGREEMENT AMONG AKANDA CORP. - and - CANNAHEALTH LIMITED - and - HOLIGEN LIMITED - and - SOMAI PHARMACEUTICALS UNIPESSOAL, LDA. Dated as of February 28, 2024 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 1.1 Definitions. 1 1.2 Exhibits, Schedules. 9 ARTICLE 2 PURCHASE OF PURCHASED INTEREST 9 2.1 Purchase of Purchased Interest 9 2.2 Purchase Price. 9 2.3 Closing. 10 2.4 |
|
| February 29, 2024 |
Exhibit 99.1 Akanda Corp. Signs Share Purchase and Escrow Agreements for the Sale of Portuguese Assets to Somai Pharmaceuticals London, February 29, 2024 – Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, today announced the signing of a definitive Share Purchase Agreement and Escrow Agreement with Somai Pharmaceuticals Unipessoal, LDA (“Somai”), |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 21, 2024 |
Akanda Corp. Provides Further Update on Annual Meeting of its Shareholders Exhibit 99.1 Akanda Corp. Provides Further Update on Annual Meeting of its Shareholders London, February 20, 2024 – Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, today announces that it has received an order from the Ontario Superior Court of Justice (the “Court”) permitting Akanda to hold its annual meeting of shareholders (the “Meeting”) on o |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 20, 2024 |
Note Conversion Agreement July 25, 2023 Exhibit 10.14 Note Conversion Agreement July 25, 2023 This Note Conversion Agreement (the “Agreement”) is made as of July 25, 2023 between Halo Collective Inc., an Ontario corporation (the “Holder”), and Akanda Corp., an Ontario corporation (the “Debtor”), in connection with a promissory note with a principal amount of US$328,000 dated January 26, 2023 issued by the Debtor to the Holder (the “Note |
|
| February 20, 2024 |
Akanda Corp. Provides Update on Annual Meeting of its Shareholders Exhibit 99.1 Akanda Corp. Provides Update on Annual Meeting of its Shareholders London, February 20, 2024 – Akanda Corp. (“Akanda” or the “Company”), an international medical cannabis company, today announces that it has made an application to the Ontario Superior Court of Justice (the “Court”) to extend the deadline for it to hold its annual meeting of shareholders (the “Meeting”) from February 2 |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 20, 2024 |
Exhibit 10.23 NON-BINDING LETTER OF INTENT STRICTLY PRIVATE AND CONFIDENTIAL November 21st, 2023 Akanda Corp. Re: Proposed Purchase of the Shares of RPK Biopharma, Unipessoal, LDA This letter of intent (“Letter of Intent”) is presented further to the discussions to date between Holigen Limited (the “Seller”), a subsidiary of Akanda Corp. (“Akanda”) and Somai Pharmaceuticals Ltd (“Somai” or the “Bu |
|
| February 20, 2024 |
INDEPENDENT CONTRACTOR AGREEMENT Exhibit 10.21 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (“Agreement”), effective as of , (the “Effective Date”), is between Akanda Corp. (“Company”) and Kiran Sidhu (“Contractor”). Scope of Services. 1. Company retains Contractor for consulting work pertaining to assisting the Company in increasing its enterprise value, in which the responsibilities of the Contractor a |
|
| February 20, 2024 |
AKAN / Akanda Corp. / Halo Collective Inc. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 AKANDA CORP. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 00971M205 (CUSIP Number) Katie Field, Chairman & CEO Halo Collective Inc. 65 Queen Street W., Suite 815 Toronto, Ontario M5H 2M5 Canada Copy to: Richard Raymer Dorsey & Whitney LLP 161 |
|
| February 20, 2024 |
AKAN / Akanda Corp. / Halo Collective Inc. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 to SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AKANDA CORP. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 00971M205 (CUSIP Number) May 27, 2023 (Date of Event Which Requires Fil |
|
| February 20, 2024 |
Exhibit 99.2 Akanda Corp. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom February 20, 2024 Re: Notice to Shareholders – Application for Extension of Time to Hold Annual General Meeting Dear valued shareholders of Akanda Corp. (“Akanda”): Akanda is a corporation incorporated pursuant to the Business Corporations Act (Ontario) (“OBCA”) under the laws of the Province of Ontario, Canada. Pursu |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. |
|
| February 20, 2024 |
Exhibit 107 Calculation Of Filing Fee Table F-1 (Form Type) Akanda Corp. (Exact name of Registrant as Specified in its Charter) Security Type (1) Security Class Title Amount Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee (3) Fees to Be Paid Common Shares, par value $0.0001 per share, to be sold by the Regis |
|
| February 20, 2024 |
AMENDMENT NO. 1 TO NON-BINDING LETTER OF INTENT Exhibit 10.24 AMENDMENT NO. 1 TO NON-BINDING LETTER OF INTENT This Amendment No. 1 to Non-Binding Letter of Intent (“Amendment”) is entered into and made effective as of January 31, 2024 by and between Akanda Corp. (“Akanda”) and Somai Pharmaceuticals Ltd. (“Somai”). Akanda and Somai are collectively referred to as the “Parties” and singularly referred to as “Party.” RECITALS WHEREAS, Akanda and S |
|
| February 20, 2024 |
AKAN / Akanda Corp. / Halo Collective Inc. - SCHEDULE 13D AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 AKANDA CORP. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 00971M205 (CUSIP Number) Katie Field, Chairman & CEO Halo Collective Inc. 65 Queen Street W., Suite 815 Toronto, Ontario M5H 2M5 Canada Copy to: Richard Raymer Dorse |
|
| February 20, 2024 |
Significant Subsidiaries of Akanda Corp. Exhibit 21.1 Significant Subsidiaries of Akanda Corp. The following corporations are wholly owned subsidiaries of Akanda Corp: Subsidiary Jurisdiction Canmart Limited England and Wales Cannahealth Limited Malta Bophelo Holdings Ltd. United Kingdom Bophelo Bio Science and Wellness (Pty) Ltd.* Lesotho Holigen Holdings Limited Malta RPK Biopharma Unipessoal, LDA Portugal 1371011 BC Ltd Canada * Bophe |
|
| February 13, 2024 |
Akanda Corp. Discusses Positive Trends in UK Cannabis Market Exhibit 99.1 Akanda Corp. Discusses Positive Trends in UK Cannabis Market London, February 13, 2024 – Akanda Corp. NASDAQ: AKAN ("Akanda" or the “Company”), provides an overview of the growing cannabis market in the United Kingdom and promising trends among patients. 2023 was a dynamic year for the UK cannabis market. Patients grew and so did imports. November of 2023 marked five years since the U |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| February 2, 2024 |
Akanda Corp. Entered into Non-Binding Letter of Intent for Sale of RPK Exhibit 99.1 Akanda Corp. Entered into Non-Binding Letter of Intent for Sale of RPK London, February 1, 2024 – Akanda Corp. ("Akanda" or the “Company”), an international medical cannabis company, today announces it has entered into an Amended Non-Binding Letter of Intent (“LOI”) with Somai Pharmaceuticals Ltd. for the sale of RPK, its Portuguese subsidiary. Pursuant to the provisions set forth in |
|
| February 2, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 1, 2024, between Akanda Corp., a Canadian corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchaser |
|
| February 2, 2024 |
PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES AKANDA CORP. Warrant Shares: 1,462,991 Initial Exercise Date: February 2, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| February 2, 2024 |
280,851 common shares Pre-funded warrants to purchase up to 1,462,991 common shares AKANDA CORP. Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 29, 2024) Registration No. |
|
| February 2, 2024 |
Akanda Corp. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Akanda Corp. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules London, February 2, 2024 - Akanda Corp. ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has entered into a securities purchase agreement with certain accredited investors whereby the investors have agreed to purchase 280,851 common shares at a purchase price of |
|
| February 2, 2024 |
Exhibit 99.2 Akanda Corp. Provides Update on Scheduling Policy in US Aims to Be Among First International Movers in US Pending Approval London, February 2, 2024 – Akanda Corp. ("Akanda" or the “Company”), an international medical cannabis company, today announces it is actively following the developments in federal US policy to reschedule and/or deschedule cannabis under the Controlled Substances |
|
| February 2, 2024 |
Akanda Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Akanda Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules London, February 2, 2024 – Akanda Corp. ("Akanda" or the “Company”), an international medical cannabis company, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 280,851 common shares at a purchase price of $0.406 per share, a |
|
| January 25, 2024 |
AKANDA CORP. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom AKANDA CORP. 1a, 1b Learoyd Road New Romney TN28 8XU United Kingdom January 25, 2024 SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Ms. Doris Stacey Gama Re: Akanda Corp. Registration Statement on Form F-3 Filed January 18, 2024 File No. 333-276577 Ladies and Gentlemen: Pursuant to Rule 461 under the Securiti |
|
| January 18, 2024 |
Exhibit 4.4 STANDARD PROMISSORY NOTE 1. THE PARTIES. This Standard Promissory Note ("Note") made on , is by and between: Borrower: RPK Biopharma, Lda with a mailing address of Av. Santa Isabel, N°7, EN249-4, 2635-047 Rio de Moure, Sintra, Portugal ("Borrower"), and Lender: ("Lender"). 2. LOAN TERMS. The Lender agrees to lend the Borrower under the following terms: a. Principal Amount: € EUR b. Int |
|
| January 18, 2024 |
Exhibit Filing Fees Calculation of Filing Fee Table F-3 (Form Type) Akanda Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee F |
|
| January 18, 2024 |
Exhibit 4.3 PROMISSORY NOTE $ USD Commencement Date: TO: Halo Collective Inc. Maturity Date: FOR VALUE RECEIVED, AKANDA CORP. (the “Debtor”) promises to pay to HALO COLLECTIVE INC. (the “Holder” ), the principal amount of DOLLARS ($,000.00) (the “Principal”) currency of the United States of America. The interest shall commence on the Effective Date of this Promissory Note (the “Note”) until paid a |
|
| January 18, 2024 |
As filed with the Securities and Exchange Commission on January 18, 2024 As filed with the Securities and Exchange Commission on January 18, 2024 Registration No. |
|
| January 4, 2024 |
Exhibit 99.1 Akanda Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule LONDON, January 4, 2024 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, announced today it received an extension of 180 calendar days from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with t |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by chec |
|
| December 29, 2023 |
Exhibit 99.1 Akanda Corp. Unaudited Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) As at June 30, December 31, Note 2023 2022 ASSETS Current Cash $ 443,338 $ 228,794 Cash held in trust — 27,009 Trade and other receivables 6 657,568 1,235,619 Prepayments 336,985 199,488 Biological assets 7 257,144 809,180 Inventory 7 1,280,073 1,057,240 Marketab |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| December 12, 2023 |
Akanda Corporation Announces CFO Exhibit 99.1 Akanda Corporation Announces CFO Appointment LONDON, December 11, 2023 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it has appointed a new Chief Financial Officer. Effective immediately Charn Deol will join the company and come to Akanda with more than 35 years of financial markets. The Boar |
|
| October 25, 2023 |
BLRX / Bioline Rx Ltd - ADR / Su Wilson - SCHEDULE 13G Passive Investment SC 13G 1 ea187238-13gsuakanda.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akanda Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 00971M106 (CUSIP Number) October 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by ch |
|
| September 25, 2023 |
AMENDED AND RESTATED OPTION TO PURCHASE Exhibit 99.1 Execution Copy AMENDED AND RESTATED OPTION TO PURCHASE THIS AMENDED AND RESTATED OPTION TO PURCHASE (THIS “AGREEMENT”) is made as of September 22, 2023. AMONG: 1107385 B.C. LTD., a British Columbia company having a mailing address of 800-1199 West Hastings St., Vancouver, BC V6E 3T5 (the “Owner”) AND: AKANDA CORP., an Ontario company having a mailing address of 1A, 1B Learoyd Road, Ne |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by ch |
|
| September 20, 2023 |
AKANDA CORP. ANNOUNCES SIGNING OF OPTION TO DEVELOP CANADIAN THC AND CBD FARMING FACILITY Exhibit 99.1 AKANDA CORP. ANNOUNCES SIGNING OF OPTION TO DEVELOP CANADIAN THC AND CBD FARMING FACILITY FRANKFURT, Germany & LONDON -(BUSINESS WIRE)- International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”) and 1107385 B.C. LTD (the “Owner”) have agreed upon terms to purchase farming land and rel |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Offices) Indicate by check |
|
| July 14, 2023 |
As filed with the Securities and Exchange Commission on July 14, 2023 As filed with the Securities and Exchange Commission on July 14, 2023 Registration No. |
|
| July 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akanda Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Proposed Maximum Security Fee Calculation Amount Registered(1) Offering Price Per Maximum Aggregate Offering Amount of Registration Security Type Class Title Rule (2) Unit(3) Price(3) Fee Rate Fee Equity Common Shares 457(c) and |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check m |
|
| July 6, 2023 |
Akanda Corp. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 Akanda Corp. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency LONDON, July 6, 2023 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that the Company has received a written notification (the “Notification Letter”) on July 3, 2023 from the Listing Qualifications Department of the Nasdaq Stock Mar |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check mar |
|
| May 30, 2023 |
AKANDA CORP. ANNOUNCES TERMINATION OF LOAN AGREEMENT Exhibit 99.1 AKANDA CORP. ANNOUNCES TERMINATION OF LOAN AGREEMENT FRANKFURT, Germany & LONDON -(BUSINESS WIRE)- International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda and Veridia Canada Ltd. (the “Lender”) have mutually agreed to terminate the loan agreement between the parties previously announced on April 18, 2023 (the “L |
|
| May 2, 2023 |
Exhibit 4.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed. SUPPLY AGREEMENT FOR EU GMP QUALITY MEDICAL CANNABIS FLOWER (DAB) BETWEEN: Supplier: RPK Biopharma Unipessoal, Lda With registered address at: Avenida de Santa Isabel, 7 2635-0 |
|
| May 2, 2023 |
LICENSE AND PACKAGING AGREEMENT Exhibit 4.12 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed. LICENSE AND PACKAGING AGREEMENT BASIC TERMS: A. CONTRACT NO: LPA – 72 B. EFFECTIVE DATE: As of July 19, 2021 (the “Effective Date”). C. PARTIES: 1L Botanicals LLC, a California |
|
| May 2, 2023 |
Exhibit 13.2 Certification of the Chief Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Shailesh Bhushan, Chief Financial Officer of Akanda Corp |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| May 2, 2023 |
Exhibit 13.1 Certification of the Chief Executive Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Katie Field, Executive Director of Akanda Corp. (the “Co |
|
| May 2, 2023 |
Exhibit 12.1 Certification of the Chief Executive Officer as required by Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Katie Field, certify that: 1. I have reviewed this annual report on Form 20-F of Akanda Corp; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| May 2, 2023 |
Exhibit 12.2 Certification of the Chief Financial Officer as required by Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Shailesh Bhushan, certify that: 1. I have reviewed this annual report on Form 20-F of Akanda Corp; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements |
|
| May 2, 2023 |
Exhibit 4.11 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed. RETAIL LICENSE AGREEMENT BETWEEN COOKIES CREATIVE CONSULTING & PROMOTIONS, INC. AND RPK BIOPHARMA UNIPESSOAL, LDA RETAIL LICENSE AGREEMENT BASIC TERMS: A.CONTRACT NO: RLA – 96 |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-41324 CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Tra |
|
| May 1, 2023 |
Akanda Corp. Announces Loan Agreement Exhibit 99.1 Akanda Corp. Announces Loan Agreement FRANKFURT and LONDON, April 28, 2023 - International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that it has entered into a loan agreement dated April 26, 2023 (the “Loan Agreement”) with Veridia Canada Ltd. (the “Lender”), in the principal amount of €500,000 (approximately C$738,650) (th |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check m |
|
| May 1, 2023 |
Exhibit 4.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed. LOAN AGREEMENT entered into by and between VERIDIA CANADA, LTD. (as Lender) – and – AKANDA CORP (as Borrower) – and – RPK BIOPHARMA, UNIPESSOAL, LDA. (as Guarantor) 26 April 202 |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check m |
|
| March 29, 2023 |
Exhibit 99.1 Akanda Corporation Has Regained Compliance with NASDAQ’s Minimum Bid Price Requirement LONDON, March 29, 2023 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, today announced that it received a notification letter (the “Notification Letter on Compliance”) from the Listing Qualifications Department of The Nasd |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check m |
|
| March 21, 2023 |
Exhibit 99.1 March 21, 2023 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street NE Washington, D.C. 20549 Re: Akanda Corp. Ladies and Gentlemen: We have read the statements in the Form 6-K dated March 21, 2023, of Akanda Corp. (“the Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm. We |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check m |
|
| March 8, 2023 |
Exhibit 99.1 Akanda Corporation Announces CFO Appointment LONDON, March 7, 2023 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it has appointed a new Chief Financial Officer. Effective immediately Shailesh Bhushan will join the company, and comes to Akanda with more than 25 years of financial and accountin |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check m |
|
| March 8, 2023 |
Exhibit 99.1 Akanda Corporation Announces 1-for-10 Reverse Stock Split LONDON, March 8, 2023 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it expects to implement a 1-for-10 reverse stock split on its ordinary shares effective Thursday March 9, with trading to begin on a split-adjusted basis at the market |
|
| March 8, 2023 |
Exhibit 99.2 Ministry of Public and Business Service Delivery Articles of Amendment Business Corporations Act Corporation Name (Date of Incorporation/Amalgamation) AKANDA CORP. (July 16, 2021) 1. The name of the corporation is changed to: Not amended 2. The number of directors or the minimum/maximum number of directors are amended as follows: Not amended 3. The articles are amended as follows: A. |
|
| February 17, 2023 |
6-K 1 tm236793d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Ex |
|
| February 17, 2023 |
Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director Exhibit 99.1 Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director LONDON, February 16th, 2023 – International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk’s Service Agreement dated June 2, 2021 (the “Service Agreement”) to an immediate end with effect from February |
|
| February 15, 2023 |
BLRX / BioLineRx Ltd. / Halo Collective Inc. - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* AKANDA CORP. (Name of Issuer) Common Shares (Title of Class of Securities) 00971M106 (CUSIP Number) Katharyn Field, 130 W Clark Street, Medford, OR 97501, (202) 498-7917 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun |
|
| February 7, 2023 |
Exhibit 99.1 Akanda Corp.’s Chief Executive Officer Submits Resignation LONDON, February 7, 2023 - International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Tejinder Virk resigned from his position as CEO and Director of the Company. Mr. Virk notified the Company of his resignation on February 3, 2023. Mr. Virk’s resignation was a |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by chec |
|
| January 9, 2023 |
BLRX / BioLineRx Ltd. / 1306077 B.C. Ltd. - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* AKANDA CORP. (Name of Issuer) Common shares (Title of Class of Securities) 00971M106 (CUSIP Number) October 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 4, 2023 |
Exhibit 99.1 Akanda Corp. Unaudited Condensed Consolidated Statements of Financial Position (Expressed in US Dollars) June 30, December 31, Note 2022 2021 ASSETS Current Cash $ 3,930,702 $ 3,495,390 Cash held in trust 4 472,512 — Trade and other receivables 5 726,865 242,357 Prepayments 380,837 107,759 Biological assets 198,631 — Inventory 895,774 — Financial asset measured at FVTPL 8 337,145 — To |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-41324 AKANDA CORP. (Registrant’s Name) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of Principal Executive Office) Indicate by check |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| December 23, 2022 |
Exhibit 99.1 Akanda Corp.?s Chief Executive Officer On Paid Leave of Absence LONDON, December 21, 2022 - International medical cannabis platform company Akanda Corp. ("Akanda" or the ?Company?) (NASDAQ: AKAN) today announced that Chief Executive Officer Tej Virk has been on a paid leave of absence both administrative and personal since November 30, 2022, pending an independent investigation being |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| November 14, 2022 |
EUROPE’S PREMIUM CANNABIS CULTIVATOR NOVEMBER 2022 Exhibit 99.1 EUROPE’S PREMIUM CANNABIS CULTIVATOR NOVEMBER 2022 DISCLAIMER FORWARD - LOOKING STATEMENTS Various statements contained in this presentation, including those that express a belief, expectation or intention, as well a s t hose that are not statements of historical fact, are forward - looking statements. These forward - looking statements may include projections and estimates concerning |
|
| November 14, 2022 |
Exhibit 99.1 AKANDA CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING TO BE HELD ON NOVEMBER 22, 2022 AND MANAGEMENT INFORMATION CIRCULAR November 1, 2022 AKANDA CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS (the "Notice") NOTICE IS HEREBY GIVEN that an annual general and special meeting (the "Meeting") of the holders (the "Shareholders") of common shares (the "Common Shares" |
|
| November 14, 2022 |
6-K 1 tm2230277d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by che |
|
| November 14, 2022 |
Exhibit 99.2 AKANDA CORP. Security Class: Common Shares FORM OF PROXY Annual General and Special Meeting to be held on Tuesday, November 22, 2022 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any adjournme |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by chec |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by chec |
|
| October 21, 2022 |
As filed with the Securities and Exchange Commission on October 21, 2022 As filed with the Securities and Exchange Commission on October 21, 2022 Registration No. |
|
| October 21, 2022 |
Exhibit 99.2 RESTRICTED SHARE UNIT award AGREEMENT pursuant to THE AKANDA CORP. 2021 Equity Incentive Plan Akanda Corp. (the "Corporation") hereby confirms the grant to [?] (the "Recipient"), effective [?] (the "Grant Date"), of [?] Restricted Share Unit Awards ("RSUs") described in the table below pursuant to the Corporation's 2021 Equity Incentive Plan (the "Plan") (as the same may be supplement |
|
| October 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akanda Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Shares 457(c) and 4 |
|
| October 21, 2022 |
Exhibit 99.3 OPTION AGREEMENT AKANDA CORP. 2021 EQUITY INCENTIVE PLAN Optionee: (name) (address) (email) Grant: Maximum Number of Common Shares Subject to Option (the "Option Shares") Type of Grant: ? Incentive Stock Options ? Non-Incentive Stock Options Option Exercise Price: $ per Option Share Date of Grant: , 20 Vesting Schedule: Expiry Date: , 20. This Option Agreement is made under and is sub |
|
| October 4, 2022 |
Akanda Corp. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 Akanda Corp. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency LONDON, October 3 - International medical cannabis platform company Akanda Corp. ("Akanda" or the ?Company?) (NASDAQ: AKAN) today announced that the Company has received a written notification (the ?Notification Letter?) on September 27, 2022 from the Listing Qualifications Department of the Nasdaq Stock |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by chec |
|
| September 28, 2022 |
Exhibit 99.1 Akanda Plans First Shipment of Medical Cannabis to Germany and Anticipates Leading Market Share Position ? Akanda prepares first export shipment to Germany of high THC indoor cultivated premium cannabis from its Portugal-based Holigen operation in the coming weeks ? Akanda aims to capture approximately 10% market share German medical cannabis imports based on recent data LONDON - Inte |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by ch |
|
| September 14, 2022 |
Exhibit 99.1 Akanda Partners with Cookies to Bring the Iconic Cannabis Brand and High THC Strains to European Consumers for the First Time Exclusive licensing agreement enables Akanda to cultivate, manufacture and sell Cookies branded products in Portugal, including operating Cookies branded pharmacy outlets London, September 13, 2022: International medical cannabis platform company Akanda Corp. ( |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by ch |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by ch |
|
| September 9, 2022 |
Exhibit 99.1 Founder of Aurora Cannabis Terry Booth, Joins Akanda as Chair of Advisory Board Proven Global Cannabis Executive Joins to Help Guide Akanda?s European Strategy London, September 8, 2022: International cannabis company Akanda Corp. ("Akanda" or the ?Company?) (NASDAQ: AKAN) today announced that Terry Booth, the founder of Aurora Cannabis Inc. (?Aurora Cannabis?) (NASDAQ: ACB) has joine |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-41324 AKANDA CORP. (Name of registrant) 1a, 1b Learoyd Road New Romney TN28 8XU, United Kingdom (Address of principal executive office) Indicate by check |
